UK Cannabis Pharmaceuticals Market Size & Outlook
Related Markets
UK cannabis pharmaceuticals market highlights
- The UK cannabis pharmaceuticals market generated a revenue of USD 383.2 million in 2023 and is expected to reach USD 6,735.4 million by 2030.
- The UK market is expected to grow at a CAGR of 50.6% from 2024 to 2030.
- In terms of segment, epidiolex was the largest revenue generating brand type in 2023.
- Other Brands is the most lucrative brand type segment registering the fastest growth during the forecast period.
Cannabis pharmaceuticals market data book summary
| Market revenue in 2023 | USD 383.2 million |
| Market revenue in 2030 | USD 6,735.4 million |
| Growth rate | 50.6% (CAGR from 2023 to 2030) |
| Largest segment | Epidiolex |
| Fastest growing segment | Other Brands |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sativex, Epidiolex, Other Brands |
| Key market players worldwide | Jazz Pharmaceuticals PLC, AbbVie Inc, Insys Therapeutics, Bausch Health Companies Inc |
Other key industry trends
- In terms of revenue, UK accounted for 11.2% of the global cannabis pharmaceuticals market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cannabis pharmaceuticals market is projected to lead the regional market in terms of revenue in 2030.
- Netherlands is the fastest growing regional market in Europe and is projected to reach USD 1,322.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cannabis Pharmaceuticals Market Scope
Cannabis Pharmaceuticals Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | View profile | 2800 | Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, Ireland, D04 E5W7 | https://www.jazzpharmaceuticals.com |
| Insys Therapeutics | View profile | 501-1000 | Chandler, Arizona, United States, North America | http://www.insysrx.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
UK cannabis pharmaceuticals market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cannabis pharmaceuticals market will help companies and investors design strategic landscapes.
Epidiolex was the largest segment with a revenue share of 50.78% in 2023. Horizon Databook has segmented the UK cannabis pharmaceuticals market based on sativex, epidiolex, other brands covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is one of the leading countries in the world in terms of granting approvals for the utilization of cannabis pharmaceuticals, such as Sativex, owing to the increasing adoption of cannabis for medical purposes, rising number of research proclaiming the benefits of cannabis in the treatment of certain medical conditions, and growing awareness about medical cannabis.
For instance, in April 2022, NHS England launched a patient registry to collect information on the prescribing of cannabis-based products for medicinal use.
Reasons to subscribe to UK cannabis pharmaceuticals market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK cannabis pharmaceuticals market databook
-
Our clientele includes a mix of cannabis pharmaceuticals market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cannabis pharmaceuticals market , including forecasts for subscribers. This country databook contains high-level insights into UK cannabis pharmaceuticals market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK cannabis pharmaceuticals market size, by brand type, 2018-2030 (US$M)
UK Cannabis Pharmaceuticals Market Outlook Share, 2023 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
